Search

Your search keyword '"Vanazzi, Anna"' showing total 212 results
Start Over Author "Vanazzi, Anna"
212 results on '"Vanazzi, Anna"'

2. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma

Author

Conconi, Annarita, Chiappella, Annalisa, Ferreri, Andrés J. M., Stathis, Anastasios, Botto, Barbara, Sassone, Marianna, Gaidano, Gianluca, Balzarotti, Monica, Merli, Francesco, Tucci, Alessandra, Vanazzi, Anna, Tani, Monica, Bruna, Riccardo, Orsucci, Lorella, Cabras, Maria Giuseppina, Celli, Melania, Annibali, Ombretta, Liberati, Anna Marina, Zanni, Manuela, Ghiggi, Chiara, Pisani, Francesco, Pinotti, Graziella, Dore, Fausto, Esposito, Fabiana, Pirosa, Maria Cristina, Cesaretti, Marina, Bonomini, Luisella, Vitolo, Umberto, and Zucca, Emanuele

Published
2024
Full Text
View/download PDF

4. Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL

Author

Mazzara, Saveria, Travaini, Laura, Botta, Francesca, Granata, Chiara, Motta, Giovanna, Melle, Federica, Fiori, Stefano, Tabanelli, Valentina, Vanazzi, Anna, Ramadan, Safaa, Radice, Tommaso, Raimondi, Sara, Lo Presti, Giuliana, Ferrari, Mahila E., Jereczek-Fossa, Barbara Alicja, Tarella, Corrado, Ceci, Francesco, Pileri, Stefano, and Derenzini, Enrico

Published
2023
Full Text
View/download PDF

5. The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade

Author

Tabanelli, Valentina, Melle, Federica, Motta, Giovanna, Mazzara, Saveria, Fabbri, Marco, Agostinelli, Claudio, Calleri, Angelica, Del Corvo, Marcello, Fiori, Stefano, Lorenzini, Daniele, Cesano, Alessandra, Chiappella, Annalisa, Vitolo, Umberto, Derenzini, Enrico, Griffin, Gabriel K., Rodig, Scott J., Vanazzi, Anna, Sabattini, Elena, Tarella, Corrado, Sapienza, Maria Rosaria, and Pileri, Stefano A.

Published
2022
Full Text
View/download PDF

6. High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies

Author

Viviani, Simonetta, primary, Vanazzi, Anna, additional, Frassoni, Samuele, additional, Rusconi, Chiara, additional, Rossi, Andrea, additional, Romano, Alessandra, additional, Patti, Caterina, additional, Schiavotto, Corrado, additional, Sorasio, Roberto, additional, Marasco, Vincenzo, additional, Lissandrini, Laura, additional, Rapezzi, Davide, additional, Gottardi, Daniela, additional, Cocito, Federica, additional, Mulè, Antonio, additional, Leotta, Salvatore, additional, Gini, Guido, additional, Sorio, Marco, additional, Derenzini, Enrico, additional, Rambaldi, Alessandro, additional, Bagnardi, Vincenzo, additional, and Tarella, Corrado, additional

Published
2024
Full Text
View/download PDF

8. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial

Author

Moccia, Alden A., Taverna, Christian, Schär, Sämi, Vanazzi, Anna, Rondeau, Stéphanie, Hitz, Felicitas, Mingrone, Walter, Pabst, Thomas, Cevreska, Lidija, del Giglio, Auro, Raats, Johann, Rauch, Daniel, Vorobiof, Daniel A., Lohri, Andreas, Ruegsegger, Céline, Biaggi Rudolf, Christine, Rusterholz, Corinne, Hayoz, Stefanie, Ghielmini, Michele, and Zucca, Emanuele

Published
2020
Full Text
View/download PDF

9. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Author

Zucca, Emanuele, Rondeau, Stephanie, Vanazzi, Anna, Østenstad, Bjørn, Mey, Ulrich J.M., Rauch, Daniel, Wahlin, Björn E., Hitz, Felicitas, Hernberg, Micaela, Johansson, Ann-Sofie, de Nully Brown, Peter, Hagberg, Hans, Ferreri, Andrés J.M., Lohri, Andreas, Novak, Urban, Zander, Thilo, Bersvendsen, Hanne, Bargetzi, Mario, Mingrone, Walter, Krasniqi, Fatime, Dirnhofer, Stefan, Hayoz, Stefanie, Hawle, Hanne, Vilei, Simona Berardi, Ghielmini, Michele, and Kimby, Eva

Published
2019
Full Text
View/download PDF

10. Dampening of cytotoxic innate lymphoid cells: A new tumour immune escape mechanism in B cell non-Hodgkin's lymphoma

Author

Roma, Stefania, primary, Camisaschi, Chiara, additional, Mancuso, Patrizia, additional, Trabanelli, Sara, additional, Vanazzi, Anna, additional, Villa, Stefania, additional, Prati, Daniele, additional, Fiori, Stefano, additional, Lorenzini, Daniele, additional, Tabanelli, Valentina, additional, Pileri, Stefano, additional, Tarella, Corrado, additional, Jandus, Camilla, additional, and Bertolini, Francesco, additional

Published
2022
Full Text
View/download PDF

12. P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers

Author

Viviani, Simonetta, primary, Vanazzi, Anna, additional, Frassoni, Samuele, additional, Rusconi, Chiara, additional, Rossi, Andrea, additional, Romano, Alessandra, additional, Patti, Caterina, additional, Schiavotto, Corrado, additional, Sorasio, Roberto, additional, Marasco, Vincenzo, additional, Lissandrini, Laura, additional, Rapezzi, Davide, additional, Gottardi, Daniela, additional, Cocito, Federica, additional, Mulè, Antonino, additional, Gini, Guido, additional, Zanotti, Roberta, additional, Rambaldi, Alessandro, additional, Bagnardi, Vincenzo, additional, and Tarella, Corrado, additional

Published
2022
Full Text
View/download PDF

13. The Impact of Segmentation Method and Target Lesion Selection on Radiomic Analysis of 18F-FDG PET Images in Diffuse Large B-Cell Lymphoma

Author

Botta, Francesca, primary, Ferrari, Mahila, additional, Raimondi, Sara, additional, Corso, Federica, additional, Lo Presti, Giuliana, additional, Mazzara, Saveria, additional, Airò Farulla, Lighea Simona, additional, Radice, Tommaso, additional, Vanazzi, Anna, additional, Derenzini, Enrico, additional, Travaini, Laura Lavinia, additional, and Ceci, Francesco, additional

Published
2022
Full Text
View/download PDF

14. Outcome of follicular lymphoma (FL) patients in maintenance with antiCD20 monoclonal antibodies (MoAb) in SARS-Cov2 era.

Author

Castellino, Alessia, primary, Castellino, Claudia, additional, Boccomini, Carola, additional, Clerico, Michele, additional, Nicoli, Paolo, additional, Vanazzi, Anna, additional, Fanelli, Fulvia, additional, Perrone, Tommasina, additional, Marchesi, Francesco, additional, Cocito, Federica, additional, Merli, Michele, additional, Bigliardi, Sara, additional, Mecacci, Bianca, additional, Bozzoli, Valentina, additional, Margiotta-Casaluci, Gloria, additional, Meli, Erika, additional, Anastasia, Antonella, additional, Farina, Lucia, additional, Annibali, Ombretta, additional, and Massaia, Massimo, additional

Published
2022
Full Text
View/download PDF

16. How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia

Author

Deodato, Marina, primary, Frustaci, Anna Maria, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Murru, Roberta, additional, Visentin, Andrea, additional, Reda, Gianluigi, additional, Mauro, Francesca Romana, additional, Quaresmini, Giulia, additional, Vanazzi, Anna, additional, Vitale, Candida, additional, Orsucci, Lorella, additional, Massaia, Massimo, additional, Sanna, Alessandro, additional, Motta, Marina, additional, Ibatici, Adalberto, additional, Ferrarini, Isacco, additional, Borella, Chiara, additional, Varettoni, Marzia, additional, Tani, Monica, additional, Marinoni, Sara, additional, Ferrario, Andrea, additional, Zamprogna, Giulia, additional, Montillo, Marco, additional, and Tedeschi, Alessandra, additional

Published
2022
Full Text
View/download PDF

17. Treatment of very high-risk classical Hodgkin Lymphoma: cases’ selection from real life and critical review of the literature

Author

Rusconi, Chiara, Ciavarella, Sabino, Fabbri, Alberto, Flenghi, Leonardo, Puccini, Benedetta, Re, Alessandro, Sorio, Marco, Vanazzi, Anna, and Zanni, Manuela

Subjects
Adult, Aged, 80 and over, Male, How I Treat, Hodgking Lymphoma, salvage treatments, Hodgkin Disease, Risk Assessment, Young Adult, Treatment Outcome, relapsed/refractory disease, Humans, Female, high risk HL patien, Neoplasm Recurrence, Local, Aged
Abstract

Over the last 4 decades, advances in radiation therapy and the addition of combination chemotherapy have significantly increased the cure rate of patients with HL, with a 5-year OS of about 90% . However, despite high rate of cure after first line of therapy, 5%-10% of HLs are refractory to the treatment, and 10-30% of patients have a disease relapse after a complete response (CR). Relapsed HL can be treated with salvage therapies with a long-lasting complete remission in 80% of cases. In recent years, novel drugs are available for the patients with relapsed/refractory HL, like Brentuximab Vedotin and immune checkpoint inhibitors. These drugs have been able to rescue a cohort of patients who subsequently could receive an allogeneic stem-cell transplant. Our cases have been chosen because they are representative of critical issues in the management of relapsed/refractory HL; our experiences are consistent with what reported by other Authors.

Published
2020

18. Follicular Lymphoma Microenvironment Signatures Define Patients Subsets Obtaining Long Term Clinical Benefit after Single-Agent First-Line Anti-CD20 Immunotherapy

Author

Derenzini, Enrico, primary, Del Corvo, Marcello, additional, Quattrocchi, Maria Chiara, additional, Castelli, Marta, additional, Sapienza, Maria Rosaria, additional, Mazzara, Saveria, additional, Fiori, Stefano, additional, Vanazzi, Anna, additional, Ramadan, Safaa M., additional, Pileri, Stefano A, additional, and Tarella, Corrado, additional

Published
2021
Full Text
View/download PDF

19. Integration of Targeted Gene Expression Profiling and FDG-PET Radiomics Uncovers Radiometabolic Signatures Associated with Outcome in Diffuse Large B-Cell Lymphoma

Author

Mazzara, Saveria, primary, Travaini, Laura L., additional, Botta, Francesca, additional, Granata, Chiara, additional, Motta, Giovanna, additional, Melle, Federica, additional, Fiori, Stefano, additional, Tabanelli, Valentina, additional, Vanazzi, Anna, additional, Ramadan, Safaa M., additional, Radice, Tommaso, additional, Raimondi, Sara, additional, Lo Presti, Giuliana, additional, Ferrari, Mahila E., additional, Cremonesi, Marta, additional, Ceci, Francesco, additional, Tarella, Corrado, additional, Pileri, Stefano A, additional, and Derenzini, Enrico, additional

Published
2021
Full Text
View/download PDF

20. The Impact of Segmentation Method and Target Lesion Selection on Radiomic Analysis of 18 F-FDG PET Images in Diffuse Large B-Cell Lymphoma.

Author

Botta, Francesca, Ferrari, Mahila, Raimondi, Sara, Corso, Federica, Lo Presti, Giuliana, Mazzara, Saveria, Airò Farulla, Lighea Simona, Radice, Tommaso, Vanazzi, Anna, Derenzini, Enrico, Travaini, Laura Lavinia, and Ceci, Francesco

Subjects
DIFFUSE large B-cell lymphomas, POSITRON emission tomography, FEATURE extraction, IMAGE analysis, COMPUTED tomography
Abstract

Featured Application: The present work contributes to the investigation on the robustness and reproducibility of radiomic studies, a fundamental step for bringing radiomics towards clinical implementation. Radiomic analysis of 18F[FDG] PET/CT images might identify predictive imaging biomarkers, however, the reproducibility of this quantitative approach might depend on the methodology adopted for image analysis. This retrospective study investigates the impact of PET segmentation method and the selection of different target lesions on the radiomic analysis of baseline 18F[FDG] PET/CT images in a population of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients. The whole tumor burden was segmented on PET images applying six methods: (1) 2.5 standardized uptake value (SUV) threshold; (2) 25% maximum SUV (SUVmax) threshold; (3) 42% SUVmax threshold; (4) 1.3∙liver uptake threshold; (5) intersection among 1, 2, 4; and (6) intersection among 1, 3, 4. For each method, total metabolic tumor volume (TMTV) and whole-body total lesion glycolysis (WTLG) were assessed, and their association with survival outcomes (progression-free survival PFS and overall survival OS) was investigated. Methods 1 and 2 provided stronger associations and were selected for the next steps. Radiomic analysis was then performed on two target lesions for each patient: the one with the highest SUV and the largest one. Fifty-three radiomic features were extracted, and radiomic scores to predict PFS and OS were obtained. Two proportional-hazard regression Cox models for PFS and OS were developed: (1) univariate radiomic models based on radiomic score; and (2) multivariable clinical–radiomic model including radiomic score and clinical/diagnostic parameters (IPI score, SUVmax, TMTV, WTLG, lesion volume). The models were created in the four scenarios obtained by varying the segmentation method and/or the target lesion; the models' performances were compared (C-index). In all scenarios, the radiomic score was significantly associated with PFS and OS both at univariate and multivariable analysis (p < 0.001), in the latter case in association with the IPI score. When comparing the models' performances in the four scenarios, the C-indexes agreed within the confidence interval. C-index ranges were 0.79–0.81 and 0.80–0.83 for PFS radiomic and clinical–radiomic models; 0.82–0.87 and 0.83–0.90 for OS radiomic and clinical–radiomic models. In conclusion, the selection of either between two PET segmentation methods and two target lesions for radiomic analysis did not significantly affect the performance of the prognostic models built on radiomic and clinical data of DLBCL patients. These results prompt further investigation of the proposed methodology on a validation dataset. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

21. MRI features of breast implant-associated anaplastic large cell lymphoma

Author

Rotili, Anna, primary, Ferrari, Federica, additional, Nicosia, Luca, additional, Pesapane, Filippo, additional, Tabanelli, Valentina, additional, Fiori, Stefano, additional, Vanazzi, Anna, additional, Meneghetti, Lorenza, additional, Abbate, Francesca, additional, Latronico, Antuono, additional, and Cassano, Enrico, additional

Published
2021
Full Text
View/download PDF

23. The identification of TCF1+progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade

Author

Tabanelli, Valentina, Melle, Federica, Motta, Giovanna, Mazzara, Saveria, Fabbri, Marco, Agostinelli, Claudio, Calleri, Angelica, Del Corvo, Marcello, Fiori, Stefano, Lorenzini, Daniele, Cesano, Alessandra, Chiappella, Annalisa, Vitolo, Umberto, Derenzini, Enrico, Griffin, Gabriel K., Rodig, Scott J., Vanazzi, Anna, Sabattini, Elena, Tarella, Corrado, Sapienza, Maria Rosaria, and Pileri, Stefano A.

Abstract

T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare and aggressive variant of diffuse large B-cell lymphoma (DLBCL) that usually affects young to middle-aged patients, with disseminated disease at presentation. The tumor microenvironment (TME) plays a key role in THRLBCL due to its peculiar cellular composition (<10% neoplastic B cells interspersed in a cytotoxic T-cell/histiocyte-rich background). A significant percentage of THRLBCL is refractory to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP)-based regimens and to chimeric antigen receptor T-cell therapy; thus, the development of a specific therapeutic approach for these patients represents an unmet clinical need. To better understand the interaction of immune cells in THRLBCL TME and identify more promising therapeutic strategies, we compared the immune gene expression profiles of 12 THRLBCL and 10 DLBCL samples, and further corroborated our findings in an extended in silico set. Gene coexpression network analysis identified the predominant role of the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis in the modulation of the immune response. Furthermore, the PD-1/PD-L1 activation was flanked by the overexpression of 48 genes related to the functional exhaustion of T cells. Globally, THRLBCL TME was highly interferon-inflamed and severely exhausted. The immune gene profiling findings strongly suggest that THRLBCL may be responsive to anti–PD-1 therapy but also allowed us to take a step forward in understanding THRLBCL TME. Of therapeutic relevance, we validated our results by immunohistochemistry, identifying a subset of TCF1+(T cell–specific transcription factor 1, encoded by the TCF7gene) progenitor exhausted T cells enriched in patients with THRLBCL. This subset of TCF1+exhausted T cells correlates with good clinical response to immune checkpoint therapy and may improve prediction of anti–PD-1 response in patients with THRLBCL.

Published
2022
Full Text
View/download PDF

25. Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): The Experience at European Institute of Oncology (EIO)

Author

Vanazzi, Anna, primary, Ramadan, Safaa, additional, De Lorenzi, Francesca, additional, Arena, Paola, additional, Derenzini, Enrico, additional, Rietjens, Mario, additional, Rotili, Anna, additional, Latronico, Antuono, additional, Travaini, Laura, additional, Omodeo Sale', Emanuela, additional, Malengo, Daniela, additional, Gerardi, Marianna, additional, Fiori, Stefano, additional, Tabanelli, Valentina, additional, Pileri, Stefano A, additional, and Tarella, Corrado, additional

Published
2019
Full Text
View/download PDF

28. Rituximab Maintenance Treatment for a Maximum of 5 Years in Follicular Lymphoma: Final Results of the Randomized Phase III Trial SAKK 35/03

Author

Taverna, Christian, primary, Martinelli, Giovanni, additional, Hitz, Felicitas, additional, Mingrone, Walter, additional, Pabst, Thomas, additional, Cevreska, Lidija, additional, del Giglio, Auro, additional, Vanazzi, Anna, additional, Laszlo, Daniele, additional, Raats, Johann, additional, Rauch, Daniel, additional, Vorobiof, Daniel, additional, Lohri, Andreas, additional, Zucca, Emanuele, additional, Rueegsegger, Celine, additional, Rondeau, Stephanie -, additional, Rusterholz, Corinne, additional, and Ghielmini, Michele, additional

Published
2018
Full Text
View/download PDF

29. Integration of Nanostring Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies

Author

Derenzini, Enrico, primary, Rossi, Alessandra, additional, Agostinelli, Claudio, additional, Rossi, Maura, additional, Melle, Federica, additional, Motta, Giovanna, additional, Fabbri, Marco, additional, Radice, Tommaso, additional, Ramadan, Safaa, additional, Vanazzi, Anna, additional, Tabanelli, Valentina, additional, Fiori, Stefano, additional, Chiappella, Annalisa, additional, Agazzi, Alberto, additional, Zinzani, Pier Luigi, additional, Vitolo, Umberto, additional, Tarella, Corrado, additional, and Pileri, Stefano A., additional

Published
2018
Full Text
View/download PDF

30. A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas.

Author

Vannata, Barbara, Vanazzi, Anna, Negri, Mara, Liptrott, Sarah Jayne, Bartosek, Anna Amalia, Miani, Monica, Di Sanzo, Alessandro, Cavalli, Franco, Zucca, Emanuele, and Stathis, Anastasios

Subjects
FEBRILE neutropenia, DRUG efficacy, LYMPHOMAS, B cell lymphoma, MYOCARDIAL infarction, PROGRESSION-free survival
Abstract

Marginal zone lymphomas (MZLs) are indolent yet incurable lymphomas with frequent relapses following therapy. For patients with relapsed/refractory disease, no standard therapies exist. Here we report results of an exploratory phase II study aimed at assessing the efficacy and safety of the alkylator agent bendamustine in combination with the second‐generation anti‐CD20 monoclonal antibody, ofatumumab, in patients with relapsed or refractory MZL. Patients with MZL and previously treated with at least one line of systemic therapy were eligible. Treatment consisted in bendamustine (90 mg/m2 on days 1 and 2) and ofatumumab (1000 mg on day 1) in 28‐day cycles for up to six cycles. Sixteen patients were included in the trial. In one patient, the diagnosis was revised after two cycles of treatment and was excluded from the efficacy analysis. Among 15 patients with MZL, 14 were evaluable for response: the overall and complete response rates were 92.9% and 57.1%, respectively. The median duration of response was 30.4 months (95% confidence interval [CI], 15.5 –not estimable) and 2‐years progression‐free survival 77% (95% CI, 43%–92%). Fifteen patients (94%) experienced grade 3–4 adverse events. Toxicity was mostly hematological. Neutropenia grade ≥3 was recorded in 27% of patients, lymphocytopenia in 93%, and infections and febrile neutropenia each in 13%. One patient discontinued treatment due to myocardial infarction; no treatment‐related deaths occurred. The combination of bendamustine with ofatumumab was active with an acceptable toxicity profile in this small phase II trial and can be considered for further investigation in relapsed/refractory MZL patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

31. Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma

Author

Broccoli, Alessandro, primary, Casadei, Beatrice, additional, Morigi, Alice, additional, Sottotetti, Federico, additional, Gotti, Manuel, additional, Spina, Michele, additional, Volpetti, Stefano, additional, Ferrero, Simone, additional, Spina, Francesco, additional, Pisani, Francesco, additional, Merli, Michele, additional, Visco, Carlo, additional, Paolini, Rossella, additional, Zilioli, Vittorio Ruggero, additional, Baldini, Luca, additional, Di Renzo, Nicola, additional, Tosi, Patrizia, additional, Cascavilla, Nicola, additional, Molica, Stefano, additional, Ilariucci, Fiorella, additional, Rigolin, Gian Matteo, additional, D'Alò, Francesco, additional, Vanazzi, Anna, additional, Santambrogio, Elisa, additional, Marasca, Roberto, additional, Mastrullo, Lucia, additional, Castellino, Claudia, additional, Desabbata, Giovanni, additional, Scortechini, Ilaria, additional, Trentin, Livio, additional, Morello, Lucia, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2018
Full Text
View/download PDF

32. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma

Author

Broccoli, Alessandro, primary, Pellegrini, Cinzia, additional, Di Rocco, Alice, additional, Puccini, Benedetta, additional, Patti, Caterina, additional, Gini, Guido, additional, Mannina, Donato, additional, Tani, Monica, additional, Rusconi, Chiara, additional, Romano, Alessandra, additional, Vanazzi, Anna, additional, Botto, Barbara, additional, Carlo-Stella, Carmelo, additional, Hohaus, Stefan, additional, Musto, Pellegrino, additional, Mazza, Patrizio, additional, Molica, Stefano, additional, Corradini, Paolo, additional, Fama, Angelo, additional, Gaudio, Francesco, additional, Merli, Michele, additional, Gravetti, Angela, additional, Gritti, Giuseppe, additional, Arcari, Annalisa, additional, Tosi, Patrizia, additional, Liberati, Anna Marina, additional, Pinto, Antonello, additional, Pavone, Vincenzo, additional, Gherlinzoni, Filippo, additional, Naso, Virginia, additional, Volpetti, Stefano, additional, Trentin, Livio, additional, Goldaniga, Maria Cecilia, additional, Bonfichi, Maurizio, additional, De Renzo, Amalia, additional, Schiavotto, Corrado, additional, Spina, Michele, additional, Storti, Sergio, additional, Carella, Angelo Michele, additional, Stefoni, Vittorio, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2017
Full Text
View/download PDF

33. Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma

Author

Pellegrini, Cinzia, primary, Broccoli, Alessandro, additional, Pulsoni, Alessandro, additional, Rigacci, Luigi, additional, Patti, Caterina, additional, Gini, Guido, additional, Mannina, Donato, additional, Tani, Monica, additional, Rusconi, Chiara, additional, Romano, Alessandra, additional, Vanazzi, Anna, additional, Botto, Barbara, additional, Santoro, Armando, additional, Hoaus, Stefan, additional, Rigolin, Gian Matteo, additional, Musto, Pellegrino, additional, Mazza, Patrizio, additional, Molica, Stefano, additional, Corradini, Paolo, additional, Fama, Angelo, additional, Gaudio, Francesco, additional, Merli, Michele, additional, Ronconi, Fioravante, additional, Gritti, Giuseppe, additional, Vallisa, Daniele, additional, Tosi, Patrizia, additional, Liberati, Anna Marina, additional, Pinto, Antonello, additional, Pavone, Vincenzo, additional, Gherlinzoni, Filippo, additional, Bianchi, Maria Paola, additional, Volpetti, Stefano, additional, Trentin, Livio, additional, Goldaniga, Maria Cecilia, additional, Bonfichi, Maurizio, additional, De Renzo, Amalia, additional, Schiavotto, Corrado, additional, Spina, Michele, additional, Carella, Angelo Michele, additional, Stefoni, Vittorio, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2017
Full Text
View/download PDF

34. Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Author

Kimby, Eva, primary, Rondeau, Stephanie, additional, Vanazzi, Anna, additional, Ostenstad, Bjorn, additional, Mey, Ulrich J.M., additional, Rauch, Daniel, additional, Wahlin, Björn E, additional, Hitz, Felicitas, additional, Hernberg, Micaela, additional, Johansson, Ann-Sofie, additional, de Nully Brown, Peter, additional, Hagberg, Hans, additional, Ferreri, Andres J.M., additional, Lohri, Andreas, additional, Novak, Urban, additional, Zander, Thilo, additional, Bersvendsen, Hanne, additional, Bergetzi, Mario, additional, Mingrone, Walter, additional, Krasniqi, Fatime, additional, Dirnhofer, Stefan, additional, Hawle, Hanne, additional, Berardi, Simona, additional, Ghielmini, Michele, additional, and Zucca, Emanuele, additional

Published
2016
Full Text
View/download PDF

35. Prognostic Value of End of Treatment FDG-PET Scan in T-Cell Lymphoma, a 20-Year Single Institution Study

Author

Derenzini, Enrico, primary, Gueli, Angela, additional, Ramadan, Safaa, additional, Vanazzi, Anna, additional, Sammassimo, Simona, additional, Gigli, Federica, additional, Frungillo, Niccolo', additional, Bruna, Riccardo, additional, Agazzi, Alberto, additional, De Crescenzo, Alberto, additional, Pastano, Rocco, additional, Travaini, Laura L, additional, Grana, Chiara, additional, Daniele, Laszlo, additional, Arcese, William, additional, and Tarella, Corrado, additional

Published
2016
Full Text
View/download PDF

36. Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma

Author

Pellegrini, Cinzia, primary, Rigacci, Luigi, additional, Patti, Caterina, additional, Gini, Guido, additional, Mannina, Donato, additional, Tani, Monica, additional, Rusconi, Chiara, additional, Romano, Alessandra, additional, Vanazzi, Anna, additional, Botto, Barbara, additional, Carlo-Stella, Carmelo, additional, Hohaus, Stefan, additional, Rigolin, Gian Matteo, additional, Musto, Pellegrino, additional, Mazza, Patrizio, additional, Molica, Stefano, additional, Corradini, Paolo, additional, Fama, Angelo, additional, Gaudio, Francesco, additional, Merli, Michele, additional, Gravetti, Angela, additional, Gritti, Giuseppe, additional, Arcari, Annalisa, additional, Tosi, Patrizia, additional, Liberati, Anna Marina, additional, Pinto, Antonello, additional, Pavone, Vincenzo, additional, Gherlinzoni, Filippo, additional, Naso, Virginia, additional, Volpetti, Stefano, additional, Visentin, Andrea, additional, Goldaniga, Maria Cecilia, additional, Bonfichi, Maurizio, additional, De Renzo, Amalia, additional, Schiavotto, Corrado, additional, Spina, Michele, additional, Storti, Sergio, additional, Carella, Angelo Michele, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2016
Full Text
View/download PDF

37. Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma

Author

Broccoli, Alessandro, primary, Pulsoni, Alessandro, additional, Rigacci, Luigi, additional, Patti, Caterina, additional, Gini, Guido, additional, Mannina, Donato, additional, Tani, Monica, additional, Rusconi, Chiara, additional, Romano, Alessandra, additional, Vanazzi, Anna, additional, Botto, Barbara, additional, Santoro, Armando, additional, Hohaus, Stefan, additional, Rigolin, Gian Matteo, additional, Musto, Pellegrino, additional, Mazza, Patrizio, additional, Molica, Stefano, additional, Corradini, Paolo, additional, Fama, Angelo, additional, Gaudio, Francesco, additional, Merli, Michele, additional, Ronconi, Fioravante, additional, Gritti, Giuseppe, additional, Vallisa, Daniele, additional, Tosi, Patrizia, additional, Liberati, Anna Marina, additional, Pinto, Antonello, additional, Pavone, Vincenzo, additional, Gherlinzoni, Filippo, additional, Cavalieri, Elena, additional, Volpetti, Stefano, additional, Visentin, Andrea, additional, Goldaniga, Maria Cecilia, additional, Bonfichi, Maurizio, additional, De Renzo, Amalia, additional, Schiavotto, Corrado, additional, Spina, Michele, additional, Carella, Angelo Michele, additional, Argnani, Lisa, additional, and Zinzani, Pier Luigi, additional

Published
2016
Full Text
View/download PDF

38. Pet-2 Positive during Frontline Therapy: An Early Unfavorable Predictor for Subsequent Salvage High-Dose Chemotherapy (HD-CT) and Autologous Stem Cell Transplant in Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Viviani, Simonetta, Vanazzi, Anna, Frassoni, Samuele, Rusconi, Chiara, Rossi, Andrea, Romano, Alessandra, Patti, Caterina, Schiavotto, Corrado, Sorasio, Roberto, Marasco, Vincenzo, Lissandrini, Laura, Rapezzi, Davide, Gottardi, Daniela, Cocito, Federica, Mulé, Antonio, Leotta, Salvatore, Gini, Guido, Sorio, Marco, Derenzini, Enrico, Rambaldi, Alessandro, Tarella, Corrado, and Bagnardi, Vincenzo

Abstract

Background: Interim PET (PET-2), performed after two cycles of chemotherapy (CT), is widely adopted to select patients (pt) with classical Hodgkin lymphoma (cHL), who might benefit from omitting radiotherapy (RT) or reducing the number of CT cycles in early stages, as well as intensifying or de-escalating first-line therapy in advanced stages. Furthermore, PET-2 has prognostic value in the front-line and in the salvage treatment. In a retrospective multicenter Italian study on patients experiencing failure of first-line treatment, we recently observed that PET-2 seems to be an early unfavorable predictor for subsequent salvage high-dose (HD) CT and autologous stem cell transplant (ASCT).

Published
2023
Full Text
View/download PDF

39. Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Author

Zucca, Emanuele, Schaer, Saemi, Vanazzi, Anna, Østenstad, Bjørn, Mey, Ulrich, Rauch, Daniel, Wahlin, Björn E., Hitz, Felicitas, Hernberg, Micaela, Johansson, Ann-Sofie, Brown, Peter de Nully, Hagberg, Hans, Ferreri, Andrés José María, Krasniqi, Fatime, Voegeli, Michèle, Novak, Urban, Zander, Thilo, Bersvendsen, Hanne, Mamot, Christoph, Mingrone, Walter, Stathis, Anastasios, Dirnhofer, Stefan, Hayoz, Stefanie, and Kimby, Eva

Abstract

Background:The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/10 randomized phase-2 trial (NCT0137605) to compare the effectiveness of rituximab (R) alone versus R combined with lenalidomide (L) as the initial treatment for symptomatic follicular lymphoma (FL). The primary endpoint analysis, which demonstrated higher complete remission (CR) rates with the combination therapy, was previously reported (Zucca et al. Blood 2019). This report provides a long-term analysis of time-to-event endpoints with a median follow-up of approximately 10 years.

Published
2023
Full Text
View/download PDF

40. Immune-Related Gene Expression Signatures Identify a Patient's Subset Achieving Durable Complete Response to Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma

Author

Nierychlewska, Paulina, Sapienza, Maria Rosaria, Davini, Alessandro, Montanari, Eugenia, Vanazzi, Anna, Viviani, Simonetta, Tabanelli, Valentina, Lemoli, Roberto Massimo, Tarella, Corrado, Pileri, Stefano, and Derenzini, Enrico

Abstract

Background:In classical Hodgkin lymphoma (cHL), 20%-30% of patients experience relapse or progressive disease after standard chemotherapy, requiring salvage treatment strategies including targeted immunotherapy with brentuximab vedotin (BV). Molecular mechanisms underlying treatment resistance to BV in cHL are still poorly understood. The unique characteristics of cHL microenvironment, which represents >90% of the cellular infiltrate, make targeted gene expression profiling (T-GEP) a suitable technique to investigate immune-related determinants of BV sensitivity.

Published
2023
Full Text
View/download PDF

42. PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).

Author

Witzig, Thomas E., primary, Tobinai, Kensei, additional, Rigacci, Luigi, additional, Lin, Tongyu, additional, Ikeda, Takashi, additional, Vanazzi, Anna, additional, Hino, Masayuki, additional, Shi, Yuankai, additional, Mayer, Jiri, additional, Costa, Luciano J, additional, Bermudez, Carlos DANIEL, additional, Zhu, Jun, additional, Belada, David, additional, Bouabdallah, Kamal, additional, Kattan, Joseph Gergi, additional, Wu, Cassandra, additional, Fan, Jenna, additional, Louveau, Anne-Laure, additional, Voi, Maurizio, additional, and Cavalli, Franco, additional

Published
2016
Full Text
View/download PDF

43. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

Author

Taverna, Christian, primary, Martinelli, Giovanni, additional, Hitz, Felicitas, additional, Mingrone, Walter, additional, Pabst, Thomas, additional, Cevreska, Lidija, additional, del Giglio, Auro, additional, Vanazzi, Anna, additional, Laszlo, Daniele, additional, Raats, Johann, additional, Rauch, Daniel, additional, Vorobiof, Daniel A., additional, Lohri, Andreas, additional, Biaggi Rudolf, Christine, additional, Rondeau, Stéphanie, additional, Rusterholz, Corinne, additional, Heijnen, Ingmar A.F.M., additional, Zucca, Emanuele, additional, and Ghielmini, Michele, additional

Published
2016
Full Text
View/download PDF

45. Rituximab Maintenance Treatment For a Maximum Of 5 Years In Follicular Lymphoma: Results Of The Randomized Phase III Trial SAKK 35/03

Author

Taverna, Christian J., primary, Martinelli, Giovanni, additional, Hitz, Felicitas, additional, Mingrone, Walter, additional, Pabst, Thomas, additional, Cevreska, Lidija, additional, del Giglio, Auro, additional, Vanazzi, Anna, additional, Laszlo, Daniele, additional, Raats, Johann, additional, Rauch, Daniel, additional, Vorobiof, Daniel A., additional, Lohri, Andreas, additional, Zucca, Emanuele, additional, Biaggi Rudolf, Christine, additional, Rondeau, Stephanie, additional, Rusterholz, Corinne, additional, and Ghielmini, Michele, additional

Published
2013
Full Text
View/download PDF

47. Chronic lymphocytic leukaemia during pregnancy: management and thoughts.

Author

Winckler, Patricia, Vanazzi, Anna, Bozzo, Maddalena, Scarfone, Giovanna, and Peccatori, Fedro A.

Subjects
*CHRONIC lymphocytic leukemia, *CHRONIC lymphocytic leukemia treatment, *PREGNANCY
Abstract

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world. Despite this fact, its coexistence with pregnancy is extremely rare, with few cases reported in the literature. Given the rarity of this event, it is difficult to conduct large prospective trials to evaluate diagnostic, management, and outcome aspects. The existing evidence is limited to the few published cases and scarce data from reviews on haematological malignancies and pregnancy. Here, we report a case of a 36-year-old patient who had already finished treatment for CLL and was under surveillance when she got pregnant. We describe the evolution of the pregnancy and of the disease's behaviour as well as the oncological and obstetrical management. Being an indolent disease, CLL during pregnancy can be usually followed up without treatment, but infectious and autoimmune complications might have a significant impact on the pregnancy outcome. Therefore, pregnancy must be closely monitored in specialised centres. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

48. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.

Author

Martinelli, Giovanni, Montoro, Juan, Vanazzi, Anna, Andreola, Giovanna, Liptrott, Sarah, Radice, Davide, Negri, Mara, Preda, Lorenzo, Pruneri, Giancarlo, and Laszlo, Daniele

Subjects
ANTINEOPLASTIC agents, CLINICAL trials, LYMPHOMAS, PROGNOSIS, RETROSPECTIVE studies, CHLORAMBUCIL, THERAPEUTICS
Abstract

Rituximab, a chimeric monoclonal antibody directed against the CD20 antigen, has been shown to be active in newly diagnosed and relapsed patients with follicular lymphoma (FL), both as monotherapy and in combination with chemotherapy. Many studies suggest that the prognosis of patients with FL may improve when it is used in combination with chemotherapy. Despite these advances, the disease remains essentially incurable with standard therapy, and novel approaches to treatment are needed because optimal therapy is not defined. The combination of chlorambucil-rituximab is one of several standard treatment options for FL. Here, we considered data arising from 75 patients with newly diagnosed FL at the European Institute of Oncology treated with the combination of rituximab plus chlorambucil. The aim of this study was to evaluate the efficacy and safety of chlorambucil and rituximab, delivered 6 mg/m(2) /day orally for 6 weeks and 375 mg/m(2) in a standard 4-weekly schedule, respectively. Patients responding to the induction therapy received a prolonged therapy with four additional cycles of chlorambucil plus rituximab. Seventy-one patients (94.6%) completed the treatment; four patients discontinued treatment because of grade 3-4 hematological toxicity. The overall response rate was 97.3% including 74.7% of complete responses. Only two patients had a stable disease at revaluation after treatment. With a median follow-up of 57 months, 72 patients (96%) are alive. Median event-free survival (EFS) and median overall survival (OS) were not reached; 5-year OS rate was 98.4%. The 5-year EFS was 71.3%. By univariate and multivariate analyses, elevated beta-2 microglobulin levels and partial responses to therapy were correlated with worse EFS. These results suggest that the combination of chlorambucil and rituximab is an active and safe regimen in patients with newly diagnosed FL, principally in those with low tumour burden and favourable prognostic factors. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results